A 58-year-old man with a 7-year history of type 2 diabetes is managed with lifestyle measures and metformin. His most recent HbA1c is 8.2 percent despite adherence. He has established atherosclerotic cardiovascular disease but normal renal function. According to Diabetes Canada pharmacologic management guidelines, which change is most appropriate?